TD Private Client Wealth LLC Trims Stake in Encompass Health Co. (NYSE:EHC)

TD Private Client Wealth LLC cut its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 66.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,485 shares of the company's stock after selling 4,851 shares during the period. TD Private Client Wealth LLC's holdings in Encompass Health were worth $229,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pathstone Holdings LLC lifted its holdings in Encompass Health by 54.5% in the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company's stock valued at $2,032,000 after purchasing an additional 7,412 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Encompass Health by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company's stock valued at $161,781,000 after buying an additional 20,547 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Encompass Health by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after buying an additional 4,345 shares in the last quarter. Central Pacific Bank Trust Division grew its stake in Encompass Health by 15.1% during the 4th quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company's stock valued at $295,000 after acquiring an additional 418 shares in the last quarter. Finally, Merit Financial Group LLC acquired a new stake in Encompass Health in the 4th quarter valued at about $374,000. 97.25% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Encompass Health Trading Down 0.1 %

NYSE EHC traded down $0.10 on Friday, reaching $101.05. The stock had a trading volume of 163,347 shares, compared to its average volume of 653,549. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The stock has a fifty day moving average price of $98.55 and a two-hundred day moving average price of $97.31. Encompass Health Co. has a 12-month low of $78.53 and a 12-month high of $104.55. The firm has a market capitalization of $10.18 billion, a price-to-earnings ratio of 22.66, a P/E/G ratio of 2.31 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. As a group, sell-side analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.67%. The ex-dividend date is Tuesday, April 1st. Encompass Health's payout ratio is currently 15.25%.

Insiders Place Their Bets

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Barclays upped their price target on Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. StockNews.com raised Encompass Health from a "hold" rating to a "buy" rating in a research note on Saturday, February 15th. William Blair reissued an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. KeyCorp upped their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $110.00 price target on shares of Encompass Health in a research report on Tuesday, February 11th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.